Most Read Articles
01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
31 Oct 2017
In patients with underlying heart failure (HF) or chronic obstructive pulmonary disease (COPD), concurrent episodes of community-acquired pneumonia increase the risk of disease exacerbations, such as short-term cardiac complications and respiratory failure, a recent study has shown.
16 Mar 2017
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
02 Nov 2017
Passive immunization with neutralizing antibodies (nAbs) do not appear to prevent transmission of HIV-1 to the infant from the infected mother’s breastmilk, a recent study suggests.

PPI use ups gastric cancer risk in H. pylori-infected patients

12 Nov 2017

In patients infected with Helicobacter pylori, long-term use of proton pump inhibitors (PPIs) is associated with an increased risk of gastric cancer (GC) even after treatment for the infection, a recent population-based study has shown.

The research team retrieved clinical information of 63,397 adults (median age at treatment 54.7 years; 46.5 percent male) who had taken at least 7 days of clarithromycin-based triple therapy for H. pylori infection. Those who failed the regimen or had been diagnosed with GC within 12 months of treatment for H. pylori were excluded.

Cox proportional hazards models were used to determine the risk of GC associated with PPI use. Propensity score adjustments were performed to control for differences in background factors.

In the cohort, 0.24 percent (n=153) developed gastric cancer following treatment for H. pylori. Of these cancers, 20.3 percent (n=31) were in the cardia and 62.1 percent (n=95) were in noncardia regions. Sites were unspecified for the remaining 17.6 percent (n=27) of the cases.

Following propensity score adjustment without trimming, PPI users were significantly at a higher risk of gastric cancer (hazard ratio [HR], 2.44; 95 percent CI, 1.42 to 4.20; p=0.002) compared with nonusers. The significant association remained after trimming (HR, 2.14; 1.27 to 3.58; p=0.004).

Multivariable analysis reflected the same elevated risk of GC after H. pylori therapy, with an HR value of 2.19 (1.31 to 3.66; p=0.003).

The difference in absolute risk of gastric cancer between patients who took PPIs and those who did not was 4.29 per 10,000 person-years after propensity score adjustments.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
31 Oct 2017
In patients with underlying heart failure (HF) or chronic obstructive pulmonary disease (COPD), concurrent episodes of community-acquired pneumonia increase the risk of disease exacerbations, such as short-term cardiac complications and respiratory failure, a recent study has shown.
16 Mar 2017
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
02 Nov 2017
Passive immunization with neutralizing antibodies (nAbs) do not appear to prevent transmission of HIV-1 to the infant from the infected mother’s breastmilk, a recent study suggests.